---
title: "US Stock Market Movement | Merck falls more than 10% after lowering adjusted earnings per share expectations"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/210226574.md"
description: "On Tuesday, Merck opened lower and fell more than 10% as of the time of publication, trading at $114.9. The company lowered its adjusted earnings per share expectations. Merck's Q2 revenue was $16.11 billion, a 7% year-on-year increase, with market expectations at $15.84 billion. The company revised its adjusted earnings per share expectations from the previous $8.53 to $8.65 down to $7.94 to $8.04. This adjustment reflects one-time costs related to the acquisitions of Harpoon Therapeutics and EyeBio, at $0.26 and $0.51 per share, respectively"
datetime: "2024-07-30T15:07:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/210226574.md)
  - [en](https://longbridge.com/en/news/210226574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/210226574.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/210226574.md) | [繁體中文](https://longbridge.com/zh-HK/news/210226574.md)


# US Stock Market Movement | Merck falls more than 10% after lowering adjusted earnings per share expectations

According to the Zhitong Finance and Economics APP, on Tuesday, Merck (MRK.US) opened low and continued to decline, with the stock falling more than 10% to $114.9 as of the time of publication. The company has lowered its adjusted earnings per share expectations.

Merck's Q2 revenue was $16.11 billion, a 7% year-on-year increase, exceeding market expectations of $15.84 billion. The company has revised its adjusted earnings per share guidance from the previous range of $8.53 to $8.65 down to $7.94 to $8.04. Merck stated that this adjustment reflects one-time expenses related to the acquisitions of Harpoon Therapeutics and EyeBio, which are $0.26 and $0.51 per share, respectively

### 相关股票

- [Merck (MRK.US)](https://longbridge.com/zh-CN/quote/MRK.US.md)

## 相关资讯与研究

- [Infinimmune, Merck enter into antibody discovery pact](https://longbridge.com/zh-CN/news/281193725.md)
- [Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential](https://longbridge.com/zh-CN/news/280868524.md)
- [GSK plc - ViiV completes changes to minority shareholding](https://longbridge.com/zh-CN/news/281310118.md)
- [GSK says bepirovirsen accepted for review in China](https://longbridge.com/zh-CN/news/280965183.md)
- [Hershey Stock (HSY) Looks Sweeter After Company Promises Return to Classic Reese's](https://longbridge.com/zh-CN/news/281415413.md)